Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is a double-blind, randomized, active-controlled, parallel group, Phase 1/3 study to compare efficacy, PK, PD and overall safety of CT-P53 with Ocrevus in patients with Relapsing-remitting Multiple Sclerosis.
CT-P53, containing the active ingredient ocrelizumab, is a humanized monoclonal antibody that is being developed as a proposed biosimilar medicinal product to Ocrevus. The purpose of this study is to demonstrate similar efficacy, PK, PD and safety of CT-P53 and Ocrevus in patients with Relpasing-remitting Multiple Screlosis.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| CT-P53 | Experimental | CT-P53(Ocrelizumab) |
|
| US-Ocrevus | Active Comparator | US-licensed Ocrevus(Ocrelizumab) |
|
| EU-Ocrevus | Active Comparator | EU-approved Ocrevus(Ocrelizumab) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| CT-P53 | Biological | Intravenous(IV) infusion |
|
|
| Measure | Description | Time Frame |
|---|---|---|
| Area under the concentration-time curve in PK group | To demonstrate PK comparability in terms of the area under the concentration time curve in patients with RRMS as follows:
| Up to Week 24 |
| Total number of new GdE lesions on T1-weighted brain MRI in Main study group | To demonstrate the equivalence of CT-P53 to reference drug (EU-Ocrevus and US-Ocrevus) in terms of efficacy in patients with RRMS as determined by the total number of new gadolinium-enhancing (GdE) lesions on T1-weighted brain magnetic resonance imaging (MRI) | Up to Week 24 |
| Measure | Description | Time Frame |
|---|---|---|
| Absoulte CD19+ B-cell counts for PD assessments | To assess PD of CT-P53 and reference drug (EU-Ocrevus and US-Ocrevus) as follows: • Absolute CD19+ B-cell counts | Up to Week 96 |
| Area under the concentration-time curve in PK group |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| SoYoung Yoo | Contact | +82 32 850 5791 | soyoung.yoo@celltrion.com | |
| JinHo Lee | Contact | +82 32 850 5787 | jinho.lee2@celltrion.com |
| Name | Affiliation | Role |
|---|---|---|
| Minji Ma | Celltrion, Inc. | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| CT-P53 3.1 investigational site | Recruiting | Poznan | Poland |
Not provided
Not provided
Not provided
Not provided
Not provided
| US-Ocrevus | Biological | Intravenous(IV) infusion |
|
|
| EU-Ocrevus | Biological | Intravenous(IV) infusion |
|
|
Area under the concentration-time curve from time zero to Week 16
| Up to Week 16 |
| Total body clearance in PK group | Total body clearance covering both administrations at Weeks 0 and 2 (CL) | Up to Week 2 |
| Volume of distribution at steady state in PK group | Volume of distribution at steady state covering both administrations at Week 0 and 2 (Vss) | Up to Week 2 |
| Safety: Immunogenecity | Number and percentage of patients with positive antidrug-antibody and neutralizing antibody results | Up to Week 96 |
| Annualized Relapse Rate (ARR) | The total number of protocol-defined MS relapses for each patient will be counted and listed. Annualized relapse rate (ARR) will be calculated by the total number of protocol-defined relapses for all patients divided by time-in-study by patient. | Up to Week 96 |
| Change in Expanded Disability Status Score (EDSS) | The EDSS score will be listed and descriptive statistics for actual value and change in EDSS score from baseline to Weeks 24, 48 and 96 will be summarized by treatment group and visit. An increase ≥1.5 point from baseline EDSS score is defined as disability progression. A reduction ≥1.0 point from baseline EDSS score is defined as disability improvement. | Up to Week 96 |
| Change in Multiple Sclerosis Functional Composite Score (MSFCS) | There are three components to the MSFCS; (1) the average scores of two trials of T25-FW (2) the average scores on the 9-HPT (the two trials for each hand are averaged, converted to the reciprocals of the mean times for each hand and then the two reciprocals are averaged) (3) the number of correct answers from the PASAT-3. Multiple Sclerosis Functional Composite Score (MSFCS) is based on the concept that scores for these three dimensions (arm, leg, and cognitive functions) are combined to create a single score (the MSFCS) that can be used to detect change over time in MS patients | Up to Week 96 |
| Total Number of Lesions on Brain Magnetic Resonance Imaging | The total number of lesions on brain MRI will be calculated as the cumulative sum of the individual number of the lesions at each scheduled visit | Up to Week 96 |
| Volume of Hypointense Lesions on T1-weighted Brain Magnetic Resonance Imaging | Actual value of volume of hypointense lesions on T1-weighted brain MRI will be listed by treatment group and visit. Descriptive statistics for actual value and change in volume of hypointense lesions on T1-weighted brain MRI from baseline to Weeks 24, 48 and 96 will be summarized by treatment group | Up to Week 96 |
| Brain Volume on Brain Magnetic Resonance Imaging | Change in brain volume is defined as the brain volume at pre-specified time point minus brain volume at baseline. Actual value of brain volume on brain MRI will be listed by treatment group. Descriptive statistics for actual value and percentage change in brain volume on brain MRI from baseline to Weeks 24, 48 and 96 will be summarized by treatment group. | Up to Week 96 |
| Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 | All reported terms of AEs will be coded to system organ class (SOC) and preferred term (PT) according to the Medical Dictionary for Regulatory Activities (MedDRA) and severity grading of AEs will be recorded according to the CTCAE Version 5.0 | Up to Week 96 |
| ID | Term |
|---|---|
| D020529 | Multiple Sclerosis, Relapsing-Remitting |
| ID | Term |
|---|---|
| D009103 | Multiple Sclerosis |
| D020278 | Demyelinating Autoimmune Diseases, CNS |
| D020274 | Autoimmune Diseases of the Nervous System |
| D009422 | Nervous System Diseases |
| D003711 | Demyelinating Diseases |
| D001327 | Autoimmune Diseases |
| D007154 | Immune System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C533411 | ocrelizumab |
Not provided
Not provided
Not provided